CLPT Clearpoint Neuro Inc
Company Analysis
Latest News
🔴 Clearpoint Neuro is trading 12.3% down in pre-market after Q2 earnings miss and revised 2026 guidance
Clearpoint Neuro is trading 12.3% down now at $14.00 after renewed attention to its second-quarter results and outlook. - Q2 revenue was $10.9 million, while...
🟢 Clearpoint Neuro rises 5.3% — Healthcare Stocks Surge on Strong Earnings Outlook and Investor Rotation
With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector experienced a significant...
🟢 Clearpoint Neuro is trading 6.4% up today on healthcare sector strength
Clearpoint Neuro is trading 6.4% up at $14.25 after recovering from the August 3 earnings-driven decline alongside broader healthcare strength. - The...
🟢 Clearpoint Neuro is trading 5.7% up in pre-market after August 3 earnings selloff
Clearpoint Neuro is trading 5.7% up at $14.15, reflecting broader healthcare strength and a rebound following its August 3 earnings selloff. - Healthcare...
Clearpoint Neuro's Cash Is Burning Fast — Can a $500 Million Dream Survive a 20% Stock Crash?
Shares of Clearpoint Neuro cratered 20.2% to $12.28 after the brain-surgery device maker reported second-quarter results that exposed a widening gap between...
🔴 Clearpoint Neuro is trading 19% down today after cutting FY2026 guidance and posting a wider-than-expected loss
Clearpoint Neuro is trading 19% down at $12.41 after its August 3 earnings report revealed a wider-than-expected quarterly loss and a downward revision to...
🔴 Clearpoint Neuro is trading 15.5% down today after cutting full-year revenue guidance and reporting a wider net loss
Clearpoint Neuro is trading at $13.00 (15.5% down) after its second-quarter earnings disappointed and management lowered full-year 2026 revenue guidance. •...
🔴 Clearpoint Neuro is trading 20.2% down today after Q2 earnings miss, revenue miss, and guidance cut
Clearpoint Neuro is trading 20.2% down at $12.28 after reporting Q2 results that missed both revenue and earnings estimates and included a full-year 2026...
ClearPoint Neuro's second quarter revenue grew 18% to $10.9M, but the company lowered its full-year 2026 guidance.
ClearPoint Neuro reported second quarter revenue of $10.9 million, an 18% increase year-over-year, which beat analyst estimates of $10.45 million. The company...
Clearpoint Neuro Inc Q2 2026 Earnings Preview: What Analysts Expect on August 03, 2026
Clearpoint Neuro is expected to report a Q2 loss of $0.29 per share on consensus revenue of $10.45 million, with the current stock price of $9.45 trading...
🔴 Clearpoint Neuro is trading 5.3% down today with no clear company-specific catalyst found
Clearpoint Neuro is trading at $14.14 (-5.33%) in after-hours trading with no clear company-specific catalyst found to explain the move from its regular...
🟢 Clearpoint Neuro is trading 5.9% up today amid broader market tailwinds
Clearpoint Neuro is trading 5.9% up at $14.95 in pre-market as broader market tailwinds and a strong risk-on tone lift equities. • The stock is rebounding...
🟢 Clearpoint Neuro is trading 5.6% up today in an isolated rebound after recent declines
Clearpoint Neuro is trading at $15.90 (5.6% up) as the stock stages an isolated rebound following a volatile week characterized by several consecutive...
🔴 Clearpoint Neuro is trading 5.2% down today amid risk-off sentiment in small-cap healthcare
Clearpoint Neuro is trading at $16.59 (5.2% down) today as the stock faces pressure from broader market weakness and a shift away from high-growth, loss-making...
🔴 Clearpoint Neuro is trading 5.6% down today amid broader market weakness and soft tech sentiment
Clearpoint Neuro is trading at $16.88 (-5.58%) in pre-market sessions as broader market weakness and uneven technology sentiment weigh on small-cap healthcare...
🟢 CLPT is trading 5.8% up today on continued momentum from uniQure Huntington’s therapy progress
CLPT is trading 5.8% up at $18.50 in pre-market, extending gains driven by its partnership with uniQure on a Huntington’s disease gene therapy. • The strength...
🔴 CLPT is trading 5.1% down today on regulatory uncertainty and weak revenue guidance
CLPT is trading 5.1% down at $17.76 in pre-market, pulling back after a recent rebound and ongoing volatility. • The stock has faced pressure in 2026 stemming...
🟢 CLPT is trading 5% up today in a rebound following recent volatility
CLPT is trading 5% up at $18.74 as the stock appears to be rebounding following a period of significant price swings. • The move follows a sharp 8.2% decline...
🟢 CLPT makes sharp 10.6% jump
CLPT is trading at $18.86, up 10.6% versus the comparison close of $17.06 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 CLPT is trading 5.8% up today as Huntington’s gene therapy data fuels extended rally
CLPT is trading at $18.05 (5.8% up), extending a sharp rally triggered by positive three-year Phase I/II data for the AMT-130 Huntington’s disease gene therapy...